Skip to main content

Multiple myeloma (plasmacytoma)

Advertisement

What is multiple myeloma?

Multiple myeloma (also known as plasmacytoma or Kahler’s disease) is a disorder of the haematopoietic system in which plasma cells become malignant. Normally, plasma cells account for less than five per cent of the cells in human bone marrow. However, in multiple myeloma, the abnormal plasma cells proliferate uncontrollably in the bone marrow and no longer respond to the body’s regulatory mechanisms. This means that the paraproteins (dysfunctional antibodies or their fragments, also known as light chains) produced by the abnormal plasma cells are generally non-functional and do not fulfil their role in defending against infection. People with multiple myeloma are therefore more susceptible to infections, despite having an increased level of antibodies. Furthermore, the larger number of plasma cells inhibits the growth of healthy haematopoietic cells in the rest of the bone marrow. Those affected may therefore suffer from symptoms such as tiredness, weakness, increased susceptibility to infection, nosebleeds and bleeding gums, bruising, and bleeding of the skin and mucous membranes. Furthermore, the abnormal plasma cells produce substances that activate bone-resorbing cells, known as osteoclasts, within the bone. If these cells become overactive, the bones – particularly in the spine, pelvis, ribs and skull – become thinner and later develop porosity (osteoporosis). In even later stages of the disease, bone defects (osteolysis) may develop, leading to fractures and/or bone pain. Blood calcium levels may also rise to dangerous levels, as calcium is released when osteoclasts break down bone. This can lead to impaired consciousness and kidney damage, potentially progressing to kidney failure. Furthermore, the protein content of the blood can rise sharply if large quantities of paraproteins are produced. This protein can block the renal tubules and severely impair kidney function. In rare cases, the paraproteins produced by the plasma cells may ‘misfold’ and be deposited as proteins in internal organs and peripheral nerves. Those affected then suffer from heart failure, kidney and liver failure, digestive problems, weight loss, numbness or tingling in the hands and feet, and an enlarged tongue. Multiple myeloma can develop unnoticed over a period of years. Symptoms usually only appear after a considerable time.

Causes and risk factors

The exact causes of multiple myeloma remain largely unclear to this day. Risk factors for developing multiple myeloma include advanced age, being male, African-American ethnicity and what is known as monoclonal gammopathy of undetermined significance (MGUS). The latter is a plasma cell disorder – or, more accurately, an abnormality detected in laboratory tests – characterised by the presence of only a small amount of paraproteins in the serum and a plasma cell proportion in the bone marrow of less than ten per cent. MGUS is usually benign but can progress to multiple myeloma. As far as genetic factors are concerned, whilst first-degree relatives of those affected do have a slight risk of developing the disease themselves, multiple myeloma is not a hereditary disease in the strict sense. Furthermore, in around half of plasmacytoma cells, the number and type of chromosomes in the genetic material are altered. A general risk factor that can trigger changes in the genetic material of cells is ionising radiation, such as that encountered in nuclear disasters or X-ray examinations; however, in the case of the latter, there is no evidence that the radiation dose increases the risk of developing multiple myeloma. Furthermore, it has been shown that congenital immunodeficiency syndromes and certain autoimmune diseases, such as rheumatoid arthritis, increase the risk of gammopathies. Links are also suspected with viral and bacterial infections that weaken the immune system (for example, HIV).

Symptoms of the disease

The symptoms of multiple myeloma are characteristic not only of this condition but also of numerous other diseases, and often only become apparent in advanced stages of the disease. The most important symptoms are:

  • Decreased physical stamina
  • Fatigue
  • Fatigue
  • Weakness

Less commonly:

  • Loss of appetite
  • Nausea
  • Vomiting
  • Weight loss

Other symptoms include:

  • Bone pain
  • Osteoporosis
  • Decline in kidney function
  • Changes in blood count
  • Anaemia
  • Increased susceptibility to infection
  • Respiratory and urinary tract infections
  • Increased tendency to bleed
  • Changes to the nervous system (e.g. paralysis, bladder and/or rectal dysfunction)

Multiple myeloma: Diagnosis

To diagnose multiple myeloma, the doctor will first take a medical history and carry out a thorough physical examination to identify any symptoms that may already have occurred. Blood and urine samples enable the type and quantity of immunoglobulins, as well as other blood parameters characteristic of the disease, to be determined. X-ray and MRI scans can detect or rule out early involvement of the spine and soft tissue lesions caused by multiple myeloma. Computed tomography (CT) is used to assess osteolytic areas in greater detail. A definitive diagnosis can only be confirmed by a bone marrow aspiration, as blood is produced in the bone marrow. During this procedure, a few millilitres of blood are taken from the pelvic bone, along with a small piece of bone.

Treatment of plasmacytoma

The aim of any treatment for multiple myeloma is the complete destruction of abnormal cells. Unfortunately, this cannot be achieved surgically in the case of plasmacytoma, as the disease is usually widespread throughout the bone marrow. As with other cancers, treatment options here include radiotherapy, systemic chemotherapy, the additional use of new drugs, a stem cell transplant, or a combination of these approaches. If the tumour is confined to a single site – which is rarely the case – radiotherapy can be very effective. However, a complete cure for multiple myeloma is not possible. Treatment therefore aims to prolong life and improve quality of life. The treatments in detail: Chemotherapy and new drugs: Chemotherapy for multiple myeloma does not have to begin immediately. It is often a case of ‘smouldering myeloma’, where, over a longer period, the condition can initially be monitored whilst the situation is assessed. In chemotherapy itself, certain cytostatic drugs are combined with corticosteroids. Furthermore, several new drugs, such as ixazomib (a proteasome inhibitor combined with an immunomodulator) or elotuzumab (monoclonal antibodies that target plasma and immune cells), are used in various combinations with corticosteroids, conventional chemotherapeutic agents or other medicines. It is important to note in this context that patients with plasmacytoma are at very high risk of infection and that the risk of infection is further increased by chemotherapy. Therefore, patients should consult a doctor immediately if they experience any signs of infection, so that the infection can be treated or so that they can take precautions themselves to prevent infections. High-dose chemotherapy and autologous stem cell transplantation (re-infusion of the patient’s own stem cells): Combining these procedures can significantly shorten the time taken for blood production to fully recover, thereby reducing the risk of infection. Allogeneic stem cell transplant (transplantation of donor stem cells): This procedure currently represents the only curative option for patients with multiple myeloma. In this procedure, the patient receives donated stem cells following chemotherapy. However, allogeneic stem cell transplantation can sometimes lead to serious complications, as, on the one hand, the risk of infection is increased and, on the other, there is a risk of a so-called graft-versus-host disease (GvHD). Radiotherapy: Special equipment – known as linear accelerators – and the latest techniques are used for radiotherapy. The aim of radiotherapy is to treat the often severe bone pain experienced by those affected. Radiotherapy can also prevent fractures in the affected bone segments and stabilise existing fractures. Radiotherapy significantly alleviates bone pain in almost all patients.

Prognosis for multiple myeloma

The prognosis is generally poor, as a permanent cure is not usually expected. However, the disease can remain relatively symptom-free for a long time, and with treatment, several periods of temporary, prolonged remission are possible. The development of new treatments (such as CAR-T cell therapy) could significantly improve the prognosis in the future.

  • Author

    Gernot Hofer

More on this topic
Hormones

Low testosterone in men: symptoms, causes and treatment

Fatigue, a reduced sex drive, and a lack of energy: these symptoms can have many causes. One possible explanation is a testosterone deficiency. However, it is not possible to determine whether testosterone levels are actually too low based solely on the symptoms or on a single blood test result.

Men's health
Men's health

PSA level: What does it mean, and when is it too high?




The PSA level is one of the best-known laboratory test results relating to the prostate. Many men come across it for the first time during a screening examination or when having symptoms investigated. An abnormal result often raises questions: Is this already a sign of prostate cancer? What levels are considered normal?

Prostate
Pollen allergy

The right diet for hay fever

Anyone suffering from hay fever should pay particular attention to their diet so as not to make the symptoms any worse.

Nutrition
Urology

Prostate health: What men need to know

The prostate is a gland in a man’s body that is only the size of a chestnut, but it plays a crucial role in well-being, urinary function and male sexuality. Benign enlargement and prostate cancer become more common in older age.

Prostate